Cotsiranib
- Generic Name
- Cotsiranib
- Drug Type
- Biotech
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 8
- Registration Number
- NCT05422378
- Locations
- 🇺🇸
Center for Clinical and Cosmetic Research, Aventura, Florida, United States
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 9
- Registration Number
- NCT05421013
- Locations
- 🇺🇸
Center for Clinical and Cosmetic Research, Aventura, Florida, United States
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 50
- Registration Number
- NCT05196373
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
- Conditions
- Squamous Cell Carcinoma in Situ
- Interventions
- Other: Placebo Saline
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 44
- Registration Number
- NCT04844983
- Locations
- 🇺🇸
Investigate MD, Scottsdale, Arizona, United States
🇺🇸Dermatology, Laser and Vein Specialists of the Carolinas, Charlotte, North Carolina, United States
🇺🇸Dermatology Associates of Knoxville, Knoxville, Tennessee, United States
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 29
- Registration Number
- NCT04844840
- Locations
- 🇺🇸
Center for Clinical and Cosmetic Research, Aventura, Florida, United States
🇺🇸Investigate MD, Scottsdale, Arizona, United States
🇺🇸Schweiger Dermatology, Hackensack, New Jersey, United States
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
- Conditions
- Hepatocellular CarcinomaLiver MetastasesCholangiocarcinoma
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 5
- Registration Number
- NCT04676633
- Locations
- 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Atlantic Health System, Morristown, New Jersey, United States
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 32
- Registration Number
- NCT04669808
- Locations
- 🇺🇸
Center for Clinical and Cosmetic Research, Aventura, Florida, United States
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
- Conditions
- Cutaneous Squamous Cell Carcinoma in SituBowen's Disease
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 25
- Registration Number
- NCT04293679
- Locations
- 🇺🇸
Center for Clinical and Cosmetic Research, Aventura, Florida, United States
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Sirnaomics
- Target Recruit Count
- 25
- Registration Number
- NCT02956317
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.